Abstract OT1-04-08: Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine

Brain Metastases ◽

Metastatic Breast ◽

Phase 3 ◽

Previously Treated ◽

Etirinotecan Pegol ◽

ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps1111 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS1111-TPS1111

Author(s):

Debu Tripathy ◽

Sara M. Tolaney ◽

Andrew David Seidman ◽

Carey K. Anders ◽

Nuhad K. Ibrahim ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Phase 3 ◽

Previously Treated ◽

Abstract OT2-07-10: ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

10.1158/1538-7445.sabcs17-ot2-07-10 ◽

2018 ◽

Author(s):

D Tripathy ◽

T Sara ◽

AD Seidman ◽

CK Anders ◽

N Ibrahim ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Phase 3 ◽

Previously Treated ◽

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

10.1158/1538-7445.sabcs15-s5-05 ◽

2016 ◽

Cited By ~ 8

Author(s):

H Wildiers ◽

S-B Kim ◽

A Gonzalez-Martin ◽

PM LoRusso ◽

J-M Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Previously Treated ◽

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

Annals of Oncology ◽

10.1093/annonc/mdy272.350 ◽

2018 ◽

Vol 29 ◽

pp. viii118

Author(s):

D. Tripathy ◽

S.M. Tolaney ◽

A.D. Seidman ◽

C.K. Anders ◽

N.K. Ibrahim ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Study ◽

Previously Treated ◽

102P Phase 3 Study Of Nktr-102 Versus Treatment of Physician's Choice (Tpc) in Patients (Pts) with Locally Recurrent or Metastatic Breast Cancer (Mbc) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Atc)

Annals of Oncology ◽

10.1016/s0923-7534(19)65753-4 ◽

2012 ◽

Vol 23 ◽

pp. ii43-ii44

Author(s):

J. Cortes ◽

E. Perez

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 3 ◽

Previously Treated ◽

Locally Recurrent ◽

OT3-01-07: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (ATC).

10.1158/0008-5472.sabcs11-ot3-01-07 ◽

2011 ◽

Author(s):

A Awada ◽

ACF Leung ◽

C Zhao ◽

AL Hannah ◽

EA Perez

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Breast Cancer Outcomes ◽

Previously Treated ◽

Locally Recurrent ◽

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Future Oncology ◽

10.2217/fon-2019-0180 ◽

2019 ◽

Vol 15 (19) ◽

pp. 2211-2225 ◽

Cited By ~ 6

Author(s):

Debu Tripathy ◽

Sara M Tolaney ◽

Andrew D Seidman ◽

Carey K Anders ◽

Nuhad Ibrahim ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Study ◽

Etirinotecan Pegol ◽

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00184-2 ◽

2011 ◽

Vol 2011 ◽

pp. 117-118

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Randomised Study ◽

137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)

Annals of Oncology ◽

10.1016/j.annonc.2020.03.238 ◽

2020 ◽

Vol 31 ◽

pp. S62-S63

Author(s):

G. Curigliano ◽

R. Murthy ◽

S. Loi ◽

A. Okines ◽

E. Paplomata ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Previously Treated

Faculty of 1000 evaluation for Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718133753.793486397 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated ◽